Global Childhood Cancer Access

By Crystal Lubbe

February 27, 2025

What if no child had to face cancer without access to treatment? The World Health Organization (WHO) has launched the Global Childhood Cancer Access initiative in collaboration with St. Jude Children’s Research Hospital. This innovative program aims to provide critically needed childhood cancer medicines to low- and middle-income countries (LMICs).

Scope and Impact

The platform has begun distributing medicines in two of the six pilot countries: Mongolia and Uzbekistan. Future shipments are planned for Ecuador, Jordan, Nepal, and Zambia. This initiative aims to reach approximately 5,000 children with cancer across at least 30 hospitals in these countries within 2025. The long-term goal is to expand to 50 countries in the next 5 to 7 years, providing access to medicines for about 120,000 children with cancer in LMICs.

Global Disparities

Childhood cancer survival rates in LMICs are significantly lower than those in high-income countries, often below 30%. This disparity arises from factors such as lack of appropriate treatment and treatment disruptions. It is estimated that 70% of children with cancer in these settings die from the disease.

Collaborative Model

The platform unites governments, the pharmaceutical industry, and NGOs in a unique collaboration, consolidating demand and shaping the market. Furthermore, it supports countries in medicine selection and develops treatment standards. Key partners, such as UNICEF Supply Division and PAHO Strategic Fund, strengthen the initiative. Moreover, it focuses on capacity building and long-term sustainability. By providing local support, data sharing, and policy development, the program helps countries maintain independent access to essential medicines.

Quotes and Statements

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, emphasised the importance of providing quality-assured cancer medicines to pediatric hospitals in LMICs, highlighting the partnership’s goal of bringing health and hope to children worldwide. James R. Downing, MD, President and CEO of St. Jude, stated that the initiative aligns with St. Jude’s founding dream: no child should die from cancer at the dawn of life, regardless of their location.

Broader Impact

The Global Childhood Cancer Access platform is part of the St. Jude Strategic Plan to accelerate progress on catastrophic childhood diseases globally. It synergises with the Global Initiative for Childhood Cancer, which supports more than 70 governments in building local cancer programs, aiming to boost survival rates to 60% by 2030.

This initiative represents a significant step toward addressing the stark disparities in childhood cancer treatment and survival rates globally, particularly in resource-limited settings. The Global Childhood Cancer Access initiative is set to reshape the future of childhood cancer care around the world.

Reference url

Recent Posts

Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics

By João L. Carapinha

September 10, 2025

Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...
Medicare ACO Outcomes: Balancing Surgical Benefits and Costs Under the TEAM Model

By João L. Carapinha

September 9, 2025

Medicare ACO outcomes are a major focus for clinicians, policymakers, and researchers seeking to understand how Accountable Care Organization (ACO) assignment influences patient results and healthcare costs after surgery. Are ACOs improving quality and saving money for Medicare patients undergoin...
UK Risks Underestimating Life Sciences Investment Potential

By Staff Writer

September 8, 2025

Life sciences investment UK is at a crucial crossroads. As the government relies on the Green Book framework to guide funding for manufacturing innovation, many experts question whether the true value of advanced life sciences manufacturing is being fully recognized. How does the current appraisa...